LivaNova PLC (LIVN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
LivaNova PLC stock (LIVN) is currently trading at $63.30. LivaNova PLC PS ratio (Price-to-Sales) is 2.45. Analyst consensus price target for LIVN is $79.91. WallStSmart rates LIVN as Underperform.
- LIVN PE ratio analysis and historical PE chart
- LIVN PS ratio (Price-to-Sales) history and trend
- LIVN intrinsic value — DCF, Graham Number, EPV models
- LIVN stock price prediction 2025 2026 2027 2028 2029 2030
- LIVN fair value vs current price
- LIVN insider transactions and insider buying
- Is LIVN undervalued or overvalued?
- LivaNova PLC financial analysis — revenue, earnings, cash flow
- LIVN Piotroski F-Score and Altman Z-Score
- LIVN analyst price target and Smart Rating
LivaNova
📊 No data available
Try selecting a different time range
Smart Analysis
LivaNova PLC (LIVN) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, institutional own.. Concerns around return on equity and eps growth. Mixed signals suggest waiting for clearer direction before acting.
LivaNova PLC (LIVN) Key Strengths (3)
Growing significantly faster than its price suggests
105.80% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
LivaNova PLC (LIVN) Areas to Watch (7)
Company is destroying shareholder value
Earnings declining -45.60%, profits shrinking
Company is losing money with a negative profit margin
Thin operating margins with cost pressures present
Revenue is fairly priced at 2.45x sales
Fairly priced relative to book value
Solid revenue growth at 12.10% per year
LivaNova PLC (LIVN) Detailed Analysis Report
Overall Assessment
This company scores 48/100 in our Smart Analysis, earning a D+ grade. Out of 10 metrics analyzed, 3 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 3.1/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Institutional Own., Market Cap. Valuation metrics including PEG Ratio (0.73) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, EPS Growth, Profit Margin. Some valuation metrics including Price/Sales (2.45), Price/Book (2.83) suggest expensive pricing. Growth concerns include Revenue Growth at 12.10%, EPS Growth at -45.60%, which may limit upside. Profitability pressure is visible in Return on Equity at -19.20%, Operating Margin at 13.00%, Profit Margin at -17.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -19.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 12.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
LIVN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
LIVN's Price-to-Sales ratio of 2.45x trades 41% below its historical average of 4.12x (21th percentile). The current valuation is 81% below its historical high of 12.83x set in Oct 2015, and 51% above its historical low of 1.62x in Apr 2025. Over the past 12 months, the PS ratio has expanded from ~1.7x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for LivaNova PLC (LIVN) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
LivaNova PLC is in a turnaround phase, with management focused on restoring profitability. Revenue reached 1.4B with 12% growth year-over-year. The company is currently unprofitable, posting a -17.5% profit margin.
Key Findings
Generating 50M in free cash flow and 82M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -17.5% profit margin. The path to breakeven will be the key catalyst.
Earnings fell 46% YoY while revenue grew 12%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact LivaNova PLC.
Bottom Line
LivaNova PLC is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About LivaNova PLC(LIVN)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.